(AIM) AIM ImmunoTech - Ratings and Ratios
Exchange: NYSE MKT • Country: United States • Currency: USD • Type: Common Stock • ISIN: US00901B1052
AIM: Immuno-Therapeutics, RNA Drug, Interferon, Cancer Treatment
AIM ImmunoTech Inc. (NYSE MKT: AIM) is a biotechnology company specializing in the development of immunotherapeutic drugs. The companys primary focus is on creating treatments for various cancers, viral infections, and immune system disorders. Its lead product, Ampligen, is a ribonucleic acid (RNA) molecule under investigation for chronic fatigue syndrome (CFS), pancreatic cancer, renal cell carcinoma, melanoma, non-small cell lung cancer, ovarian cancer, breast cancer, colorectal cancer, and prostate cancer. Ampligen is also being studied for myalgic encephalomyelitis (ME), Hepatitis B, HIV, COVID-19, and post-COVID conditions. Additionally, the company offers Alferon N Injection, an alpha interferon treatment for human papillomavirus (HPV) and genital warts. AIM ImmunoTech has established collaborations with several research institutions and pharmaceutical companies, including Amarex Clinical Research, University of Cagliari, and Erasmus University Medical Center. Formerly known as Hemispherx Biopharma, the company rebranded as AIM ImmunoTech in August 2019. Founded in 1966, it is headquartered in Ocala, Florida.
Based on the provided
Additional Sources for AIM Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
AIM Stock Overview
Market Cap in USD | 9m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 1996-07-12 |
AIM Stock Ratings
Growth 5y | -97.4% |
Fundamental | - |
Dividend | 0.0% |
Rel. Strength Industry | -62.4 |
Analysts | 4.5/5 |
Fair Price Momentum | 0.06 USD |
Fair Price DCF | - |
AIM Dividends
No Dividends PaidAIM Growth Ratios
Growth Correlation 3m | -81.6% |
Growth Correlation 12m | -95.8% |
Growth Correlation 5y | -95.2% |
CAGR 5y | -44.53% |
CAGR/Max DD 5y | -0.46 |
Sharpe Ratio 12m | -1.61 |
Alpha | -77.12 |
Beta | 1.19 |
Volatility | 95.64% |
Current Volume | 509.5k |
Average Volume 20d | 711.7k |
As of March 16, 2025, the stock is trading at USD 0.12 with a total of 509,484 shares traded.
Over the past week, the price has changed by -12.78%, over one month by -10.08%, over three months by -44.76% and over the past year by -65.22%.
No, based on ValueRay Analyses, AIM ImmunoTech (NYSE MKT:AIM) is currently (March 2025) a stock to sell. It has a ValueRay Growth Rating of -97.38 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AIM as of March 2025 is 0.06. This means that AIM is currently overvalued and has a potential downside of -50%.
AIM ImmunoTech has received a consensus analysts rating of 4.50. Therefor, it is recommend to buy AIM.
- Strong Buy: 1
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, AIM AIM ImmunoTech will be worth about 0.1 in March 2026. The stock is currently trading at 0.12. This means that the stock has a potential downside of -50%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 2.8 | 2191.7% |
Analysts Target Price | 2.8 | 2191.7% |
ValueRay Target Price | 0.1 | -50% |